Evaluations › Karolinska · Last reviewed 2026-05-16

Karolinska University Hospital (May 2021)

Summary

Astrid Lindgren Children’s Hospital, the paediatric hospital of Karolinska University Hospital, issued a guideline in April 2021, effective 1 May 2021, stating that hormonal treatment (puberty blockers and cross-sex hormones) would no longer be started for patients with gender dysphoria, except within a clinical trial approved by the Swedish ethical review authority. The guideline pointed to the lack of evidence on long-term consequences and to possible adverse effects such as cardiovascular disease, osteoporosis, infertility, increased cancer risk and thrombosis (source).

1. Content of the policy document

The Karolinska document stated:

  • In the version of March 2021 (effective 1 April 2021): no hormonal treatment is started for patients under 16 (source).
  • For patients aged 16 to 18 (March version): treatment only within a clinical trial approved by the ethical review authority, with comprehensive information on the risks and a careful assessment of the patient’s maturity to consent.
  • For patients already in treatment, the responsible physician makes a careful individual assessment of whether treatment should be stopped or continued.
  • The guideline referred to the SBU overview of 2019, the NICE evidence reviews of October 2020 and the Bell v Tavistock judgment of 1 December 2020 (source).

2. International resonance

The guideline itself refers to the changes the NHS made after the Bell v Tavistock judgment of December 2020 (source). In December 2022 the Swedish Socialstyrelsen followed with a national recommendation that limits these treatments to exceptional cases, preferably within research (source).

See also